- Clinical Trials
AUSTIN, TX, May 20, 2014 – Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways.
AUSTIN, TX, April 26, 2012
A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients. The clinical trial results were published April 26, 2012 in a paper entitled, “Phase I Clinical Trial of Systemically Administered …
CHICAGO, IL and AUSTIN, TX, April 2, 2012 – Genprex, Inc.
New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago IL. The study, “Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC” (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center. …
AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ – A new patent covering tumor suppression technologies, including the company’s lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors includes TUSC2, also known as FUS1, the anti-cancer agent in Oncoprextherapy which is undergoing clinical evaluation for lung cancer patients in the U.S….
AUSTIN, TX, September 6, 2011 – Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™.
“We are establishing the Oncoprex brand in the oncology sector in recognition of our advancing development programs.
AUSTIN, TX, July 14, 2011 – Genprex, Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services. The patent is one of 23 patents, pending or issued worldwide, licensed exclusively to Genprex, Inc….
AUSTIN, TX, June 28, 2011 – Genprex, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services. U.S. Patent No. 7,902,441 is one of 23 patents, pending or issued worldwide, that Genprex, Inc….
Oncoprex™ Phase I clinical trial data presented at the 2011 Annual Meeting of the American Association for Cancer Research in Orlando, Florida. Dr Charles Lu of MD Anderson Cancer Center presented the award winning abstract and poster describing the phase I, dose escalation trial investigating Oncoprex as a monotherapy in patients with recurrent and metastatic non-small cell lung cancer….